Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: ##STR00001##
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

The present invention relates to an acetal compound of the following general formula (1) and an acetal compound of the following general formula (2). The present invention relates to processes for preparing the acetal compound (2), comprising subjecting the acetal compound (1) to a hydrogenation reaction to form the acetal compound (2). The present invention provides a process for preparing 2,3,4,4-tetramethylcyclopentanecarbaldehyde of the following formula (3), comprising subjecting the acetal compound (2) to a hydrolysis reaction to form 2,3,4,4-tetramethylcyclopentanecarbaldehyde (3). ##STR00001##

The present invention relates to the field of perfumery. More particularly, it relates to a compound of formula (I) as defined herein below, and its uses as perfuming ingredient, to control arthropods or as antimicrobial ingredient. Therefore, following what is mentioned herein, the present invention comprises the invention compound as part of a perfuming composition or of a perfumed consumer product. Moreover, the present invention relates to a properfume compound suitable to release the compound of formula (I).

Suggested is fragrance composition comprising or consisting of a selection of specific nitriles showing improved stability against decomposition and discoloration.

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

The present disclosure is directed to novel derivatives of naturally occurring humulones and lupulones, methods of making them, compositions comprising them, and methods for using them.

A process for extracting isoprene from a pyrolysis gas mixture or a C5 fraction wherein isoprene is purified by plural extractive distillations in the presence of a polar solvent and cyclopentadiene is effectively removed and recycled as a feedstock without being converted into its dimer, dicyclopentadiene. The isoprene recovered from the process described is more than 99.5% pure.

An organic reductant, in particular an organo silicon reductant suitable for activating supported catalysts of the type MO.sub.nE.sub.m, wherein E is S and/or Se, in particular MO.sub.n, wherein M is W, Mo or Re, is described as well as its use in metathesis reactions. The reduced catalysts are able to metathesize olefins at low temperatures and are therefore also suitable for metathesis of functionalized olefins.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.